Page 17 - Drug Controller News Today

Photo Credit: IANS IANSLive New Delhi, Jan 2 (IANS) The Subject Expert Committee of Central Drug Standard Control Organization on Saturday recommended Bharat Biotechs Covaxin for emergency use in India. The final decision on its approval will, however, be taken by the Drug Controller General of India (DCGI). To get full access of the story, click here to subscribe to IANS News Service © 2021 IANS India Private Limited. All Rights Reserved. The reproduction of the story/photograph in any form...

Photo Credit: IANS IANSLive New Delhi, Jan 2 (IANS) The Subject Expert Committee of Central Drug Standard Control Organization on Saturday recommended Bharat Biotechs Covaxin for emergency use in India. The final decision on its approval will, however, be taken by the Drug Controller General of India (DCGI). To get full access of the story, click here to subscribe to IANS News Service © 2021 IANS India Private Limited. All Rights Reserved. The reproduction of the story/photograph in any form...

Updated Jan 01, 2021 | 14:40 IST The Union Health Ministry had on Thursday said that a dry run for the coronavirus vaccination will take place across India on January 2. Union Health Minister Harsh Vardhan&nbsp | &nbspPhoto Credit:&nbspANI Key Highlights A dry run for the coronavirus vaccination will take place in all States and UTs on January 2, says Health Ministry Union Health Minister Harsh Vardhan reviews preparedness ahead of Covid vaccine dry run across India New ...

Highlights Union Health Minister Dr Harsh Vardhan held a review meeting with Delhi government for the preparation of the crucial programme. Dr Harsh Vardhan said that the main aim of the dry run is to research the minutest details in detail. He said that the lists of health workers have been created. Just a day before the dry run of COVID-19 vaccination drive, Union Health Minister Dr Harsh Vardhan on Friday (January 1) held a review meeting with Delhi government for the preparation of the cruc...

COVID-19 vaccine- Serum Institute of India In a major hope to battle the global pandemic, India has now granted approval to Covishield, Serum Institute of India’s vaccine candidate, as per sources. Gearing up for to begin the process of immunisation, a high-level meeting was also convened today today. Post which, it was announced that a dry vaccine drive that will be starting tomorrow, January 2. UK has already given its nod to the AstraZeneca vaccine for emergency use. Covishield vaccine is...

Ahead of the dry-run for COVID-19 vaccine in the national capital, Union Health Minister Harsh Vardhan on Friday held a review meeting with the Delhi government officials for the preparations of the mock drill, which is scheduled for January 2. The minister was speaking to the Delhi government officials via video-conference. He said the procedure of the vaccination drive is similar to the election preparations. "The procedure of the vaccination drive is the same as the election. In any elect...

Union Minister Harsh Vardhan (File Photo) Medical teams should be trained for COVID-19 vaccination on lines of preparations made during elections: Harsh Vardhan ANI | Updated: Jan 01, 2021 19:05 IST By Ashoke Raj New Delhi [India], January 1 (ANI): Union Health Minister Harsh Vardhan on Friday chaired a high-level meeting to review preparedness at session sites across the country for COVID-19 vaccination trial run on Saturday and said just like preparatio...

Aditi Tandon New Delhi, December 30 The UK regulator on Wednesday approved the Oxford University Astra Zeneca COVID-19 vaccine for emergency use in its population a day after the country reported a whopping 40,000 new cases as it reeled under the impact of a new more infectious mutant strain. India has yet to give its approval to the vaccine.  The Drug Controller of India, which held a meeting on a pending application from Serum Institute of India for emergency use approval of the vaccine, ask...

Last Updated: BBLs Covaxins Phase-1 Trials Interim Findings Indicate Vaccine well-tolerated Interim findings from phase-1 trials of BBLs Covaxin was well-tolerated in all dose groups with no serious adverse events, as it awaits DGCIs emergency nod As both Serum Institute of India (SII) and Bharat Biotech Ltd (BBL) await the Drug Controller of India (DGCI)s approval of emergency use of their Coronavirus (COVID-19) vaccines, interim findings from phase-1 trials of BBLs Covaxin was well-toler...